An era without effective antimicrobial therapeutics is rapidly approaching, with documented cases of extensively drug resistant pathogens like Mycobacterium tuberculosis, and emphasises the urgency for developing alternatives to those therapeutics that are currently available. Targeted therapeutics provide a means of improved drug efficacy and reducing host toxicity that may result from higher doses and non-specific binding. The community of commensal microorganisms that live on and in humans, i.e., the microbiota, is also often disrupted by the use of current antimicrobial therapies through non-specific binding. There is growing evidence that supports the importance of this natural flora in development, as well as mental and physical health. Disruption of the community by antimicrobials can result in the development of infections by opportunistic pathogens, such as Clostridium difficile.
New antimicrobial concepts with fewer complications are urgently needed. One of the new strategies to eradicate pathogenic microorganisms is antimicrobial photodynamic therapy (PDT). One of the challenges for antimicrobial PDT to be of clinical use is an access to an effective delivery system for a photosensitizer drug. In our research we aim to test the applicability of both carbohydrate recognition pehomenon and nanoparticles as a possible solution for the delivery problem.